Evidence map›Paper›PMID 32774837›Full record

ReviewHepatic oncology2020

Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review.

Abdalla Aly, Sarah Ronnebaum, Dipen Patel, Yunes Doleh, Fernando Benavente

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hepatic oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Abdalla AlyAstraZeneca, Gaithersburg, MD 20878, USA.ORCID https://orcid.org/0000-0001-7411-894X
Sarah RonnebaumPharmerit - an OPEN Health Company, Bethesda, MD 20814, USA.ORCID https://orcid.org/0000-0003-4787-754X
Dipen PatelPharmerit - an OPEN Health Company, Bethesda, MD 20814, USA.ORCID https://orcid.org/0000-0002-9793-7611
Yunes DolehAstraZeneca, Gaithersburg, MD 20878, USA.ORCID https://orcid.org/0000-0002-4561-8328
Fernando BenaventeAstraZeneca, Gaithersburg, MD 20878, USA.ORCID https://orcid.org/0000-0002-3079-1996

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo describe the epidemiologic, humanistic and economic burdens of hepatocellular carcinoma (HCC) in the USA. MATERIALS &

methodsStudies describing the epidemiology and economic burden from national cohorts, any economic models, or any humanistic burden studies published 2008-2018 were systematically searched.

resultsHCC incidence was 9.5 per 100,000 person-years in most recent data, but was ∼100-times higher among patients with hepatitis/cirrhosis. Approximately a third of patients were diagnosed with advanced disease. Patients with HCC experienced poor quality of life. Direct costs were substantial and varied based on underlying demographics, disease stage and treatment received. Between 25-77% of patients did not receive surgical, locoregional or systemic treatment.

conclusionBetter treatments are needed to extend survival and improve quality of life for patients with HCC.

Indexed as

epidemiologyhepatocellular carcinomapharmacoeconomicsrisk factorsstaging

Identifiers

PMID32774837
PMCPMC7399607

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.